Relmada Therapeutics, Inc.
March 13, 2024 - by Joey Ramson
$RLMD, which focuses on the research and development of transformative medicines for those living with central nervous system (CNS) disorders, currently has its lead candidate REL-107 in Phase 3 trials.
